TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
  • News & Media
    • Press Releases
    • Media & Articles
    • Theralink Blog
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • Conference Abstracts
    • FAQ
  • Investor Relations
    • Market Opportunity
    • Investor Relations Email Alerts
    • Company Information
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Contact
    • Investors Relations FAQ
  • Contacts

News and Media

Theralink   →  Media Room
Posted on April 25, 2022

Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry

Theralink currently supports preclinical and clinical studies across 18 biopharma clients, including multinational corporations...
Read More
Posted on March 28, 2022

Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care

Theralink’s RPPA (Reverse Phase Protein Array) Technology to be deployed to support and enhance Genomic insights and may ultima...
Read More
Posted on March 21, 2022

Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients

Denver, Colorado — March 21, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision med...
Read More
Posted on March 14, 2022

Early Results Show >90% Actionability and >75% Clinical Utility for Theralink® Technologies’ Lab Developed Test for Advanced Breast Cancer Patients

Denver, Colorado — March 14, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision onc...
Read More
Posted on March 1, 2022March 1, 2022

Theralink® Technologies Announces Change of Ticker Symbol and CUSIP

DENVER, February 24, 2022 -- Theralink® Technologies - (OTC: THER) ("Theralink" or the "Company"), announces today that it has...
Read More
Posted on November 23, 2021November 23, 2021

Theralink® Technologies Announces an Update on its Securities

DENVER, October. 22, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecu...
Read More
Posted on March 29, 2021March 30, 2021

Theralink® Technologies Achieves Major Milestone: California Clinical and Public Health License for its Golden, CO Laboratory

DENVER, March. 29, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine and mol...
Read More
Posted on February 25, 2021March 30, 2021

Theralink® Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer

DENVER, Feb. 22, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"),  In a recent announcement by R...
Read More
Posted on February 3, 2021

Theralink® Technologies Announces Milestone Event–The Commencement of Testing on its First Patients

DENVER, Jan. 27, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecular...
Read More
Posted on January 6, 2021

Theralink® Technologies Issues Letter to Shareholders

DENVER, Colorado — January 6, 2021 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular pro...
Read More
1 2 3 Next page

Recent Posts

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
  • Early Results Show >90% Actionability and >75% Clinical Utility for Theralink® Technologies’ Lab Developed Test for Advanced Breast Cancer Patients
  • Theralink® Technologies Announces Change of Ticker Symbol and CUSIP
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
Copyright © 2022 Theralink. All rights reserved.